



Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.

Arthritis Rheum. 2013 Feb;65(2):529-38.

Younger J, Noor N, McCue R, Mackey S.

OBJECTIVE: To determine whether low dosages (4.5 mg/day) of naltrexone reduce fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication and extension study of a previous clinical trial, we tested the impact of low-dose naltrexone on daily self-reported pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality, and fatigue.

METHODS: Thirty-one women with fibromyalgia participated in the randomized, double-blind, placebo-controlled, counterbalanced, crossover study. During the active drug phase, participants received 4.5 mg of oral naltrexone daily. An intensive longitudinal design was used to measure daily levels of pain.

RESULTS: When contrasting the condition end points, we observed a significantly greater reduction of baseline pain in those taking low-dose naltrexone than in those taking placebo (28.8% reduction versus 18.0% reduction; $P = 0.016$). Low-dose naltrexone was also associated with improved general satisfaction with life ($P = 0.045$) and with improved mood ($P = 0.039$), but not improved fatigue or sleep. Thirty-two percent of participants met the criteria for response (defined as a significant reduction in pain plus a significant reduction in either fatigue or sleep problems) during low-dose naltrexone therapy, as contrasted with an 11% response rate during placebo therapy ($P = 0.05$). Low-dose naltrexone was rated equally tolerable as placebo, and no serious side effects were reported.

CONCLUSION: The preliminary evidence continues to show that low-dose naltrexone has a specific and clinically beneficial impact on fibromyalgia pain. The medication is widely available, inexpensive, safe, and well-tolerated. Parallel-group randomized controlled trials are needed to fully determine the efficacy of the medication.

*Exclusive formulations available through
InHealth Specialty Pharmacy*

Naltrexone 4.5mg Capsules

(Available 0.5mg – 6mg capsules)



Additional References

- ❖ Gold MS, Dackis CA, Pottash AL, et al. Naltrexone, opiate addiction, and endorphins. *Medical Res Rev* 1982;2:211–246.
- ❖ Smith JP, Stock H, Bigaman S, et al. Low-dose naltrexone therapy improves active Crohn's disease. *Am J Gastroenterol* 2007;102:820–828.
- ❖ Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. *Mult Scler* 2008;14:1076–1083.
- ❖ Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferonalpha with naltrexone. *Cancer Invest* 1995;13:561–566.
- ❖ Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. *Pain Medical* 2009;10:663–672.
- ❖ Younger, J, Noor, N, Mccue, R, Mackey, S. Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. *Arthritis & Rheumatism*. 2013:529–538.
- ❖ Younger, J, Parkitny, L, McClain, D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. *Clin Rheumatol Clinical Rheumatology*. 2014:451–459.
- ❖ Liu B, Hong JS. Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration: Dissociation from the involvement of opioid receptors. *Methods Mol Medical* 2002;79:43–54.
- ❖ Liu B, Du L, Kong LY, et al. Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia cocultures. *Neuroscience* 2000;97:749–756.
- ❖ Czlonkowski A, Stein C, Harz A. Peripheral mechanisms of opioid antinociception in inflammation: Involvement of cytokines. *Eur J Pharmacol* 1993;242:229–235.
- ❖ San-Emeterio EP, Hurlé MA. Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice. *Neurosci Lett* 2006;403:276–279.
- ❖ Bihari B (2013) Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. *Altern Ther Health Med* 19(2):56–65
- ❖ Chopra, P, Cooper, MS. Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). *Journal of Neuroimmune Pharmacology J Neuroimmune Pharmacol*. 2013:470–476.
- ❖ Donahue, RN, McLaughlin, PJ, Zagon, IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. *Gynecologic Oncology*.:382–388.
- ❖ Meng, J, Meng, Y, Plotnikoff, NP, Youkilis, G, Griffin, N, Shan, F. Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs). *International Immunopharmacology*.:1084–1089.
- ❖ Rahn, KA, McLaughlin, PJ, Zagon, IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. *Brain Research*.:243–253.